Wegovy and Mounjaro are both once-weekly injections that work by taming appetite — but they're not the same medicine, and the right choice depends on your goals, your budget and how your body responds.
Here's the comparison we walk patients through at our West Bromwich weight loss clinic every week.
Wegovy (semaglutide) acts on one appetite hormone, GLP-1, and delivered around 15% average body-weight loss in its main trial. Mounjaro (tirzepatide) acts on two hormones, GLP-1 and GIP, and delivered around 20% at the top dose — currently the strongest results of any licensed weight loss medicine. That gap is why Mounjaro is the most popular choice in our clinic.
Both share the same family of side effects — nausea, constipation, tiredness in the early weeks — managed the same way, by starting low and building the dose gradually. Both are once-weekly pens. Wegovy builds from 0.25mg to 2.4mg; Mounjaro from 2.5mg up to 15mg. Some evidence suggests Mounjaro's gut side effects are comparable or slightly milder dose-for-dose, but individual experience varies more than averages do.
Prefer tablets? Wegovy oral gives you the same semaglutide in a once-daily tablet. Watching the budget? Alli (orlistat 60mg) works completely differently — blocking about a third of dietary fat — at a fraction of the price. Our suitability wizard factors in your preference and budget before recommending anything.
The honest answer to 'which is better?' is: the one you'll stay on, at a dose you tolerate, with support that keeps you consistent. That's what the free consultation is for.
1 Lyng Lane, West Bromwich B70 7RW · Mon–Fri 8:30am–6pm, Sat 9am–1pm · 0121 500 5756
Get a personal recommendation →